Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
The Rutherford Cancer Centres and Elekta are bringing the next generation of personalised adaptive radiotherapy technology to oncology centres across the UK, with the new MR-linac Elekta Unity now available at the Rutherford Cancer Centre North West in Liverpool.
Mr Henry Cain qualified in 2001 from Leicester Medical School. Following being awarded MD in breast cancer signalling pathways and higher surgical training in Newcastle upon Tyne, he spent a year as the Oncoplastic Fellow at the Canniesburn Unit in Glasgow.
Henry Cain was appointed a Consultant Oncoplastic Surgeon at the Royal Victoria Infirmary Newcastle upon Tyne in 2013, and continues his commitment in teaching advanced oncoplastic breast surgery. Clinically he has been one of the lead surgeons in the introduction of Radioactive Seed Localisation of impalpable breast cancer and Targeted Axillary Dissection to the UK.
After growing up in rural Northumberland it was no accident that Henry returned to live in this beautiful area. He's kept very busy doing outside work with his two boys and spends most of his family time outside in the wilds with his five dogs.
Royal College of Surgeons Edinburgh
Association of Breast Surgeons
Henry Cain maintains numerous research activities in the molecular basis of breast cancer supervision MD and PhD students and has a significant interest in the use of Neo-Adjuvant Chemotherapy to de-escalate breast cancer surgery. He's the principal investigator in four national breast cancer trials and the surgical co-investigator for the national NOSTRA trial. He's also NIHR breast cancer research lead for the North of England.
Mr Henry Cain does not hold a share or financial interest in the Rutherford Cancer Centres or another Rutherford Health plc company.
Mr Henry Cain does not have a share or financial interest in equipment used at the Rutherford Cancer Centres or another Rutherford Health plc company.
Mr Henry Cain does not hold any paid advisory role(s) at the Rutherford Cancer Centres or on behalf of Rutherford Cancer Centres or Rutherford Health plc.